| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| B Lerer, F Macciardi, R H Segman, R Adolfsson, D Blackwood, S Blairy, J Del Favero, D G Dikeos, R Kaneva, R Lilli, I Massat, V Milanova, W Muir, M Noethen, L Oruc, T Petrova, G N Papadimitriou, M Rietschel, A Serretti, D Souery, S Van Gestel, C Van Broeckhoven, J Mendlewic. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Molecular psychiatry. vol 6. issue 5. 2001-10-18. PMID:11526472. |
substantial evidence supports a role for dysfunction of brain serotonergic (5-ht) systems in the pathogenesis of major affective disorder, both unipolar (recurrent major depression) and bipolar. |
2001-10-18 |
2023-08-12 |
human |
| W Pitchot, C Herrera, M Anssea. HPA axis dysfunction in major depression: relationship to 5-HT(1A) receptor activity. Neuropsychobiology. vol 44. issue 2. 2001-10-04. PMID:11490174. |
major depression is associated with a dysfunction of the serotonergic activity and the hypothalamic-pituitary-adrenal (hpa) axis. |
2001-10-04 |
2023-08-12 |
Not clear |
| S Wissink, B van der Burg, B S Katzenellenbogen, P T van der Saa. Synergistic activation of the serotonin-1A receptor by nuclear factor-kappa B and estrogen. Molecular endocrinology (Baltimore, Md.). vol 15. issue 4. 2001-09-20. PMID:11266506. |
the ability of estrogen to modulate serotonergic function raises the possibility that it may play a role in the mechanism associated with depression and its treatment. |
2001-09-20 |
2023-08-12 |
Not clear |
| K J Ressler, C B Nemerof. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and anxiety. vol 12 Suppl 1. 2001-08-23. PMID:11098410. |
role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. |
2001-08-23 |
2023-08-12 |
Not clear |
| A S Kienke, J F Rosenbau. Efficacy of venlafaxine in the treatment of severe depression. Depression and anxiety. vol 12 Suppl 1. 2001-08-23. PMID:11098414. |
given the heterogeneous nature of severe depression, reports suggesting noradrenergic as well as serotonergic system involvement in depressive disorders, and the substantive capability of both clomipramine and tca-ssri combination to treat severe depression, investigation of dual-action antidepressant agent efficacy in the treatment of severe depression is warranted. |
2001-08-23 |
2023-08-12 |
Not clear |
| M Bixo, P Allard, T Bäckström, T Mjörndal, S Nyberg, O Spigset, I Sundström-Poroma. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology. vol 26. issue 6. 2001-08-23. PMID:11403977. |
changes in serotonergic parameters have been reported in psychiatric conditions such as depression but also in the premenstrual dysphoric disorder (pmdd). |
2001-08-23 |
2023-08-12 |
Not clear |
| M Taylo. Psychological consequences of surgical menopause. The Journal of reproductive medicine. vol 46. issue 3 Suppl. 2001-08-02. PMID:11304879. |
depression seems to be increased at times of changing hormone levels in women, possibly a result of the effect of estrogen levels on serotonergic activity and its impact on other neurotransmitters. |
2001-08-02 |
2023-08-12 |
Not clear |
| S M Dursun, J R Blackburn, S P Kutche. An exploratory approach to the serotonergic hypothesis of depression: bridging the synaptic gap. Medical hypotheses. vol 56. issue 2. 2001-08-02. PMID:11425295. |
an exploratory approach to the serotonergic hypothesis of depression: bridging the synaptic gap. |
2001-08-02 |
2023-08-12 |
Not clear |
| R C Shelton, L L Brow. Mechanisms of action in the treatment of anxiety. The Journal of clinical psychiatry. vol 62 Suppl 12. 2001-07-19. PMID:11430613. |
basic research and clinical research suggest that serotonergic agents may be preferentially effective for symptoms of general distress, whereas catecholaminergic agents may target anhedonic depression symptoms. |
2001-07-19 |
2023-08-12 |
Not clear |
| K P Lesc. Serotonergic gene expression and depression: implications for developing novel antidepressants. Journal of affective disorders. vol 62. issue 1-2. 2001-06-14. PMID:11172874. |
serotonergic gene expression and depression: implications for developing novel antidepressants. |
2001-06-14 |
2023-08-12 |
Not clear |
| C H Jeng, J R Chou, B J Hoffer, Y Wan. Serotonergic modulation of ethanol-induced electrophysiological depression in young and aged rats. Alcoholism, clinical and experimental research. vol 24. issue 11. 2001-05-31. PMID:11104121. |
serotonergic modulation of ethanol-induced electrophysiological depression in young and aged rats. |
2001-05-31 |
2023-08-12 |
rat |
| P C Jobe, J W Dailey, J F Wernick. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Critical reviews in neurobiology. vol 13. issue 4. 2001-05-24. PMID:11028680. |
through studies of innate pathophysiology, noradrenergic and serotonergic deficits have been identified in individuals with depression and in animal models of epilepsy, as well as in some humans with epilepsy. |
2001-05-24 |
2023-08-12 |
human |
| R Stain-Malmgren, A E Khoury, A Aberg-Wistedt, A Tha. Serotonergic function in major depression and effect of sertraline and paroxetine treatment. International clinical psychopharmacology. vol 16. issue 2. 2001-05-17. PMID:11236074. |
serotonergic function in major depression and effect of sertraline and paroxetine treatment. |
2001-05-17 |
2023-08-12 |
human |
| A Weizman, R Weizma. Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Pharmacogenomics. vol 1. issue 3. 2001-04-26. PMID:11256582. |
the selective serotonin re-uptake inhibitors (ssris) which modulate serotonergic activity are effective in the treatment of serotonin-related mental disorders, such as depression and anxiety. |
2001-04-26 |
2023-08-12 |
Not clear |
| M Hillbrand, B M Waite, D S Miller, R T Spitz, V M Lingswile. Serum cholesterol concentrations and mood states in violent psychiatric patients: an experience sampling study. Journal of behavioral medicine. vol 23. issue 6. 2001-04-12. PMID:11199085. |
these findings are consistent with the cholesterol-serotonin hypothesis and with the substantive literature linking both aggression and depression to depressed central serotonergic activity. |
2001-04-12 |
2023-08-12 |
Not clear |
| P Boye. Do anxiety and depression have a common pathophysiological mechanism? Acta psychiatrica Scandinavica. Supplementum. issue 406. 2001-02-22. PMID:11131467. |
to review, examine and propose a common mechanism for anxiety and depression based on modifications observed in neurotransmitter systems (mainly noradrenergic and serotonergic) and dysregulation of the hypothalamic-pituitary-adrenal (hpa) axis. |
2001-02-22 |
2023-08-12 |
Not clear |
| C A Marsden, S C Stanfor. CNS drugs III: psychotherapeutics. Expert opinion on investigational drugs. vol 9. issue 8. 2001-01-18. PMID:11203476. |
the main areas covered were how serotonergic ligands could he used with greater effect in depression and schizophrenia, the therapeutic value of serotonin noradrenaline uptake inhibitors (snris) and the potential clinical value of new amine re-uptake inhibitors. |
2001-01-18 |
2023-08-12 |
Not clear |
| P Moore, H P Landolt, E Seifritz, C Clark, T Bhatti, J Kelsoe, M Rapaport, J C Gilli. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 23. issue 6. 2001-01-04. PMID:11063917. |
its current popularity was stimulated by reports that rtd reversed the antidepressant effects of selective serotonin reuptake inhibitors (ssris) and monoamine oxidase inhibitors (maois) in remitted patients with a history of depression but not in patients treated with antidepressants which promote catecholaminergic rather than serotonergic neurotransmission (such as tricyclic antidepressants or buproprion). |
2001-01-04 |
2023-08-12 |
Not clear |
| J Semb. [Clinical significance of selective serotonin reuptake inhibitor (SSRI) in the treatment of depression]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. vol 116. issue 2. 2000-12-13. PMID:10976459. |
since ssri primary acts on the serotonergic system, wide use of this drug has questioned the postulated dichotomy of the biological hypothesis of depression, the so-called serotonin depression or norepinephrine depression. |
2000-12-13 |
2023-08-12 |
Not clear |
| J Gallinat, R Bottlender, G Juckel, A Munke-Puchner, G Stotz, H J Kuss, P Mavrogiorgou, U Heger. The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology. vol 148. issue 4. 2000-12-12. PMID:10928314. |
a serotonergic dysfunction is supposed to play a pathogenetic role in depression, but there is a considerable number of non-responders in the acute treatment of depression with serotonergic agents like ssri. |
2000-12-12 |
2023-08-12 |
human |